ABSTRACT

Objective: To determine the hepatoprotective effect of Aqueous extract of Stem Bark of Berberis Lycium Royale in Isoniazid (INH) induced hepatotoxicity in mice.
Study Design: Experimental study.
Place and Duration of Study: The study was conducted from 7th April 2014 till 7th May 2014 at animal house of National Institute of Health, Islamabad.
Materials and Methods: Fifty six male albino Balb/C mice were randomly divided into four groups i.e Group I: Control group (C), Group II: Drug treated group (D), Group III: Low Aqueous group (LA), Group IV: High Aqueous group (HA) of 14 mice each. INH (50 mg/kg) was given to induce hepatotoxicity in all groups except control group (C). Aqueous extract of stem bark of Berberis Lycium Royale was given in low doses (150 mg/kg) to Low Aqueous group (LA) and in high doses (200 mg/kg) to High Aqueous group (HA). Blood samples were collected at day (0, 15th & 30th) for estimation of Liver function tests (LFTs). At the end samples for liver histopathology were taken.

Results: INH produced severe hepatotoxicity as depicted by raised LFT's & severe steatosis, hepatocytic ballooning & inflammation. In animals of Low Aqueous group (LA) and High Aqueous group (HA), serum levels of biomarkers were decreased and their liver sections showed improved histological picture but the reduction in toxic effects were more pronounced in animals treated with high Aqueous group. (HA).

Conclusion: Aqueous extract of stem bark of Berberis Lycium Royale has more significant hepatoprotective potential in high doses as compare to low doses.

Key words: Steatosis, Liver Function Tests (LFT's), Hepatoprotective, Isonizaid (INH), Berberis Lycium Royale.
induced hepatotoxicity in mice model.

Materials and Methods
An explorative animal study was carried out in animal house of National Institute of Health (NIH), Islamabad from 7th April 2014 till 7th may 2014. A total of fifty six healthy male albino Balb/C mice, weighing 28-38g and aged between 6-8 weeks, having normal LFT’s were included in study. All mice were acclimatized for one week. Then they were randomly divided in four groups (group I-IV), each group containing 14 mice (n=14). Group I (n=14) served as the normal control group (C) given normal diet and fresh water orally. Group II was Drug treated group (D) given INH (50mg/kg body wt) Group III was Low dose Aqueous extract (LA) group received low dose (150 mg/Kg body wt) & Group IV was High dose Aqueous extract (HA) group given high dose (200 mg/Kg body wt) of aqueous extract of stem bark of Berberis Lycium Royle along with INH (50 mg/kg body wt). The herb and the drugs were given orally for four consecutive weeks. Mice were housed under controlled conditions of room temperature 20 ± 2 °C, relative humidity 50% - 70% and 12-h light-dark cycle. They were provided free access to water ad libitum. All mice received the care in accordance with the NIH guidelines.

The stem bark of Berberis Lycium Royle was collected from village Prang, Charsadda. It was identified by a botanist Ghulam Jillani at Herbarium section of Botany department, Peshawar University. It was then washed with water thoroughly and shade dried. It was grounded into a fine powder with the help of an electrical grinder and taken into a non-metallic jar. The bark powder was soaked in distilled water for 72 hours with periodic stirring. It was then filtered using Whatmann filter paper no 1. The filtrate was evaporated at 55 °C in a rotary evaporator at the research laboratory of Riphah Institute of Pharmaceutical Sciences (RIPS), Islamabad. The extract was obtained as a dark brown semi-solid sticky paste. It was stored in air tight glass bottles, protected from light and kept in refrigerator at 2-8 °C to be used throughout the experiment. The yield of aqueous extract of stem bark of Berberis lycium Royle was about 25%. Blood samples of 2 mice from each group were collected at day 0 for baseline LFT’s & at day 15th for evaluation of progress of research. Finally blood samples of 10 mice from each group were taken at day 30th for final evaluation of LFT’s. Blood samples of 2 ml were collected in sterile vacuotainer with gel by performing cardiac puncture. All blood samples were allowed to clot and serum was separated from the clotted blood samples by centrifugation at 3000 rpm for 10min, using bench top centrifuge machine. All of the serum samples were stored in serum cups at -20°C until used for biochemical evaluation. ALT, AST & ALP were estimated by commercially available kits (Merck pharma) & total bilirubin by (Spectrum Diagnostics kit). Serum ALT, AST, was estimated by IFCC, ALP by Optimised standard method & total bilirubin by Calorimetric method. At the end of experiment liver samples were removed and preserved in 10% formalin after anesthetizing mice. Slides were prepared and stained by using haematoxylin and eosin (H & E stain). Microscopic study of slides was done under 40X objective for steatosis, hepatocytic ballooning and inflammatory infiltrates. Descriptive statistics were applied using one way ANOVA test on SPSS 20. The level of significance was pre-defined as <0.05 (p<0.05).

Results

Effect of Berberis lycium Royale on serum Alanine aminotransferase (ALT) levels
Isoniazid caused significantly increased level of serum ALT (183.1 ± 63.32) in mice of drug treated group (D) as compared to control group C (53 ± 4.99), but these levels were further reduced in mice of (LA) group (78.90 ± 3.85) and more significantly reduced in (HA) group (58.3 ± 3.93) treated with Berberis lycium Royale. (Table I)

Effect of Berberis Lycium Royale on serum Aspartate aminotransferase (AST)levels
Results showed that level of serum AST was significantly increased (p<0.001) in mice of drug treated group (D) given INH as compared to control group C; but these levels were further reduced in mice of (LA) group (78.90 ± 3.85) and more significantly reduced in (HA) group (58.3 ± 3.93) treated with Berberis Lycium Royale. (Table I)

Effect of Berberis Lycium Royale on serum Alkaline phosphatase (ALP) levels
Serum ALP level was significantly increased (p<0.001) in mice of drug treated group (D) given INH as compared to control group (C), but these levels were greatly reduced in mice of (LA) group and more significantly reduced in (HA) group treated with Berberis Lycium Royale.
(HA) group treated with Berberis Lycium Royale. Effect of Berberis Lycium Royale on serum total bilirubin levels. Similar results were observed for serum total bilirubin levels showing slight reduction in (LA) group followed by significant reduction (p<0.001) in (HA) group both treated with Berberis Lycium Royale.

**Histopathological Examination**

Histological examination of H & E preparations of liver specimen of control group (C) showed normal gross appearance i.e. reddish brown color of liver having smooth surfaces, microscopically normal lobular appearance having normal central vein, portal tract and radiating cords of hepatocytes (Fig 1).

Drug treated group (D) mice who were given INH, showed moderate to severe liver damage characterized by severe steatosis, marked hepatocytic ballooning and heavy inflammatory infiltrates (Fig 2).

Histological examination of H & E preparations of liver specimen of aqueous extract treated group revealed reversal to mild perivenular inflammation, mild portal inflammation, mild intralobular inflammation, mild steatosis and few ballooned cells in low dose (150mg/Kg) and minimal inflammation, minimal steatosis, minimal hepatocytic ballooning in high doses treated group(200 mg/Kg) (Fig 3).

---

**Table I: Comparison Of Liver Function Tests (LFT's) in different Groups**

<table>
<thead>
<tr>
<th>Animal Group No. (n=10)</th>
<th>T.Bil (mg/dl)</th>
<th>ALT (U/L)</th>
<th>AST(U/L)</th>
<th>ALP(U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (C)</td>
<td>0.10 ± 0.0</td>
<td>53 ± 4.99</td>
<td>107.1 ± 18.46</td>
<td>88.6 ± 1.24</td>
</tr>
<tr>
<td>Group II (D)</td>
<td>1.26 ± 0.069</td>
<td>183.1 ± 63.32</td>
<td>428.9 ± 55.32</td>
<td>173.6 ± 28.89</td>
</tr>
<tr>
<td>Group III (LA)</td>
<td>0.50 ± 0.226</td>
<td>78.90 ± 3.85</td>
<td>263.5 ± 28.72</td>
<td>99.1 ± 3.93</td>
</tr>
<tr>
<td>Group IV (HA)</td>
<td>0.19 ± 0.137</td>
<td>58.3 ± 3.93</td>
<td>117.9 ± 16.97</td>
<td>87.8 ± 1.66</td>
</tr>
</tbody>
</table>

*p-value < 0.001* (LA) group treated with Berberis Lycium Royale.

**Table II: Post-hoc comparison of Total bilirubin & ALT between the groups**

<table>
<thead>
<tr>
<th>Group Comparisons</th>
<th>Total Bilirubin Mean difference</th>
<th>p-value</th>
<th>ALT Mean difference</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C vs. Group D</td>
<td>-1.16</td>
<td>&lt; 0.001*</td>
<td>-130.1</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Group C vs. Group LA</td>
<td>-0.40</td>
<td>&lt; 0.001*</td>
<td>-25.9</td>
<td>0.522</td>
</tr>
<tr>
<td>Group C vs. Group HA</td>
<td>-0.09</td>
<td>0.855</td>
<td>-5.30</td>
<td>0.999</td>
</tr>
<tr>
<td>Group D vs. Group LA</td>
<td>0.76</td>
<td>&lt; 0.001*</td>
<td>104.2</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Group D vs. Group HA</td>
<td>1.07</td>
<td>&lt; 0.001*</td>
<td>124.8</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Group LA vs. Group HA</td>
<td>0.31</td>
<td>0.003*</td>
<td>20.6</td>
<td>0.744</td>
</tr>
</tbody>
</table>

**Table III: Post-hoc comparison of AST & ALP between the groups**

<table>
<thead>
<tr>
<th>Group Comparisons</th>
<th>AST Mean difference</th>
<th>p-value</th>
<th>ALP Mean difference</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C vs. Group D</td>
<td>-321.8</td>
<td>&lt; 0.001*</td>
<td>-85.0</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Group C vs. Group LA</td>
<td>-156.4</td>
<td>0.008</td>
<td>-10.5</td>
<td>0.993</td>
</tr>
<tr>
<td>Group C vs. Group HA</td>
<td>-10.8</td>
<td>1.000</td>
<td>0.8</td>
<td>1.000</td>
</tr>
<tr>
<td>Group D vs. Group LA</td>
<td>165.4</td>
<td>0.004*</td>
<td>74.5</td>
<td>0.002*</td>
</tr>
<tr>
<td>Group D vs. Group HA</td>
<td>336.7</td>
<td>&lt; 0.001*</td>
<td>85.8</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Group LA vs. Group HA</td>
<td>171.3</td>
<td>0.003*</td>
<td>11.3</td>
<td>0.990</td>
</tr>
</tbody>
</table>

*p = value Significant (ALT= Alanine aminotransferase, AST= Aspartate aminotransferase, ALP=AlkalinePhosphatase, T. Bil=Total Bilirubin)
Discussion
Hepatotoxicity is a common side effect when treating TB patients during anti-tuberculosis treatment. Hepatotoxicity due to anti-tubercular drugs is found to be mediated through oxidative stress and free radical damage to hepatocytes. It is documented that in sub-acute and chronic inflammation, reactive oxygen species (ROS) play a major role in modulating the degree of inflammatory response and subsequent tissue and cell injury. Antioxidants are well considered as probable protective agents in decreasing the oxidative damage of human body from ROS and impede the progress of many diseases.

Berberis Lycium is found as a best source of free radical scavenging compounds. Our study was designed to explore the hepatoprotective effect of aqueous extract of Berberis Lycium Royale. Our study results showed that aqueous extract of stem bark of Berberis Lycium Royle has significant hepatoprotective activity (p < 0.001) in dose-dependent manner. High dose of extract (200mg/kg body wt) lowered ALT, AST, ALP and total bilirubin (LFTs) level to a greater extent as compared to low dose (150mg/kg body wt). Significant elevation was noticed in levels of serum ALP, AST, ALT, and total bilirubin in group D which were given combination of isoniazid and rifampicin as compared to group C mice which received no medications. Increased levels of (LFTs) are markers of hepatotoxicity. Combined administration of high dose (200mg/kg) Berberis Lycium Royle aqueous extract with isoniazid and rifampicin in high aqueous (HA) group, restored ALP, AST, ALT, serum total bilirubin towards normal level as compared to drug treated group (D). It was most probably due to anti-oxidant effect of Berberis Lycium Royle. Our research results are in accordance with study carried by Khan & his colleagues in 2011 which showed hepatoprotective activity of aqueous extract of Berberis Lycium Royale in combination with Gallium aparine & Pistacia Integerrima in Ccl4 treated rabbits. Our research results are also found in correlation with another study showing hepatoprotective effect of Berberis Lycium in six poly herbal formulations including Livokin (Herbo-med, Kolkata) in paracetamol induced hepatotoxic mice model. Studies have been done on combination of Berberis Lycium Royale with other herbs regarding hepatoprotective activity. No study has been done individually on aqueous extract of stem bark of Berberis Lycium Royale regarding hepatoprotective activity. Our research results proved the hepatoprotective effect of aqueous extract of stem bark of Berberis Lycium Royale individually.

No histopathological studies of liver specimens have been done to explore the hepatoprotective role of Berberis Lycium Royale. In our study there was greasy appearance and yellow discoloration of liver specimens in drug treated group (D) given isoniazid. Similar observations were recorded by Imber in 2002 while doing research on hepatic steatosis and its relationship to liver transplantation. Steatosis is the most important histological feature of drug induced liver injury (DILI). In our research moderate to severe steatosis was observed in most of the mice of drug treated group (D) (Figure 22). Similar results were also observed by Hassan in 2012 while inducing hepatotoxicity in rabbit by using isoniazid. Mice treated with Berberis Lycium Royle showed reverse steatotic changes produced by isoniazid giving evidence of hepatoprotective potential in experimental groups which received extracts of Berberis Lycium Royale. Hepatocytic ballooning is the important marker to distinguish steatohepatitis from simple steatosis. It is the most important characteristic feature of steatohepatitis. In our study there was prominent ballooning in many heptocytes of drug treated group (D) which received isoniazid. Our study results correlate with the
research done by Maryam in 2010 who induced hepatotoxicity in rabbits by isoniazid. Similar results were also found by Hassan in 2012 while doing research on the effect of Nigella sativa (Black seeds) in isoniazid (INH)-induced hepatotoxicity in rabbits.

Our study results showed that aqueous extract of Berberis Lycium Royale significantly reversed hepatocytic ballooning with best reversal in high dose aqueous extract treated group as compare to low dose aqueous extract treated group. Severe inflammation was observed in drug treated group (D) given isoniazid. Drug treated group (D) showed severe inflammation. Our results are in accordance with the study done by Hassan in 2012 while inducing hepatotoxicity in rabbit by using isoniazid.

Our research results indicate that aqueous extract of Berberis Lycium Royale significantly reverse inflammatory changes (p<0.001) with more best reversal obtained with high dose (200 mg/Kg body wt) aqueous group (H A).

Histopathological changes induced by isoniazid were improved after giving aqueous extract of Berberis Lycium Royle. Hepatoprotective activity may be due to presence of antioxidant properties of flavonoids present in the Berberis Lycium Royle. No study has been done to find the hepatoprotective effect of aqueous extract of Berberis Lycium Royle individually. Our research results proved the hepatoprotective effect of aqueous extracts of stem bark of Berberis Lycium Royle.

Conclusion
Aqueous extract of stem bark of Berberis Lycium Royle has significant hepatoprotective potential in isoniazid induced hepatotoxicity in male mice model in a dose dependent manner.

REFERENCES